Acuity Inc.’s Board of Directors has raised the quarterly dividend by 17% to US$0.20 per share from US$0.17, payable on February 13, 2026, to shareholders of record on February 2, 2026. This dividend ...

Acuity Brands Inc () has held its Q1 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful investin ...

Artist, inventor and anatomist Leonardo da Vinci was the definition of a Renaissance man — and scientists are aiming to ...

Background To evaluate the efficacy and safety of repeated low-level red-light (RLRL) therapy for controlling myopia ...

A novel treatment that uses a disintegrating matrix for sustained release of medication led to improvement in vision and reduced supplemental treatment in patients with diabetic macular edema, ...

Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...

What do most people misunderstand about an eye exam? The eyes often reveal the earliest signs of conditions that affect ...

Acuity stock is dropping today despite delivering a perfectly fine earnings report.

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Dr. Jeff Goldberg explains visual acuity. Deputy AG Todd Blanche could face sanctions ‘A successful night': Kennedy Center pushes back on historic low ‘Honors' ratings Rob Gronkowski reveals he’s ...

In DME, 1 year with faricimab can expand VA in treatment-naïve eyes, maintain vision in those previously treated, and lengthen interval after loading doses. Faricimab demonstrates a rapid capability ...